Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Total Environ ; 834: 155314, 2022 Aug 15.
Article in English | MEDLINE | ID: mdl-35447194

ABSTRACT

Organosulfates (OSs) are important secondary organic aerosol (SOA) species in atmospheric fine particles (PM2.5) and can be considered as molecular indicators of SOA. To understand their seasonal and diurnal distribution characteristics and formation mechanism in northern China, PM2.5 samples collected in daytime and nighttime in winter and summer 2019 in Tianjin, China were studied for total OSs and three OS species (methyl sulfate (MS), glycolic acid sulfate (GAS), benzyl sulfate (BS)). The S contents of total OSs (SOSs) in winter and summer were 0.6 ± 1 µg m-3 and 0.4 ± 0.3 µg m-3, respectively, in PM2.5. BS found to be less abundant among the measured species, and accounted for only 0.8%-4.8% of methyl sulfate (MS), and 0.01%-0.3% of glycolic acid sulfate (GAS). Average content of GAS was higher in summer than in winter, while that of MS and BS were opposite. The fractions of MS, GAS, and BS in SOSs were higher in daytime than that in night during winter, despite their concentrations were higher in nighttime, indicating that the concentrations of unidentified OS species were much higher in nighttime than in daytime. Such diurnal variations implied that relative humidity (RH) played a major role in the formation processes of OSs, especially biogenic OSs and the acid catalyzed reaction of SO42- might be a main pathway of OSs formation during winter. High T, RH and O3 determined biological GAS in summer, while NO2 and SO2 determined anthropogenic OSs in winter. We also found that the fractions of SOSs in S contents of organic sulfur (SOS) and the S contents of MS + GAS+BS (SMS+GAS+BS) in SOSs were accounted for only less than 10% and 5%, respectively. Therefore, this study suggests the components of OS and OSs in PM2.5 have not been discovered fully yet and needs further research.


Subject(s)
Air Pollutants , Particulate Matter , Aerosols/analysis , Air Pollutants/analysis , China , Environmental Monitoring , Particulate Matter/analysis , Seasons , Sulfates/analysis
2.
J Pharm Biomed Anal ; 205: 114297, 2021 Oct 25.
Article in English | MEDLINE | ID: mdl-34391137

ABSTRACT

One potential unknown impurity was detected during the analysis of stability batches of brimonidine tartrate (BMT) in the level ranging from 0.03 % to 0.06 % by high-performance liquid chromatography (HPLC). Based on the liquid chromatography-mass spectrophotometry (LC-MS) analysis, the unknown impurity structure was presumed as 3,6,11,13,16-pentaazatetracyclo [8.6.0.0²,7.0¹²,¹6] hexadeca-1,3,5,7,9,12-hexaene. The proposed structure was elucidated, after its isolation using preparative liquid chromatography from the impurity enriched reaction crude sample, using analytical applications such as 1D NMR (1H, 13C and DEPT-135), 2D NMR (HMBC and COSY), high-resolution mass spectrometry (HRMS) and infrared spectroscopy (IR). The unknown impurity was prepared from brimonidine by following Ullman coupling reaction in the presence of CuBr2 in gram scale with optimum purity to use further in analytical developments. The identification, structural elucidation and synthesis of unknown degradation impurity such as BMT-cyclized impurity, and HPLC method validation were reported for the first time in this paper.


Subject(s)
Drug Contamination , Tandem Mass Spectrometry , Brimonidine Tartrate , Chromatography, High Pressure Liquid , Chromatography, Liquid , Spectrophotometry, Infrared
3.
J Pharm Biomed Anal ; 137: 268-278, 2017 Apr 15.
Article in English | MEDLINE | ID: mdl-28183048

ABSTRACT

During the optimization of process, eight impurities (CLB Imp-A to CLB Imp-H) were detected in few of the laboratory batches of clobazam, used as anxiolytic agent, in the range of 0.02-0.12% using gradient HPLC method with UV detection. On the basis of co-spiking analysis, six impurities (CLB Imp-A to -F) enumerated by European Pharmacopoeia, however, not reported in the earlier literature, have been harmonized and found to be two impurities are completely unknown (CLB Imp-G and -H). These two new impurities structures were presumed based on LC-ESI/MSn study as 8-chloro-1-methyl-5-phenyl-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione (CLB Imp-G) and 5-chloro-1-methyl-3-phenyl-1H-benzo[d]imidazol-2(3H)-one (CLB Imp-H). The presumed impurities structures were confirmed by their synthesis followed by the complete spectral analysis such as ESI-MS, 1D NMR (1H, 13C and DEPT), 2D NMR (HSQC, HMBC and COSY) and IR, and chromatographic retention time profile. Identification, synthesis, structural characterization, prospects to the formation and controlling of these new impurities were described in detail and reported first in this paper.


Subject(s)
Anti-Anxiety Agents/analysis , Anti-Anxiety Agents/chemistry , Benzodiazepines/chemistry , Drug Contamination/prevention & control , Chromatography, High Pressure Liquid/methods , Clobazam , Imidazoles/chemistry , Magnetic Resonance Spectroscopy/methods , Spectrometry, Mass, Electrospray Ionization/methods
4.
J Pharm Anal ; 7(6): 394-400, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29404065

ABSTRACT

One unknown impurity (Imp-II) during the analysis of laboratory batches of isoproterenol hydrochloride was detected in the level ranging from 0.04% to 0.12% by high performance liquid chromatography with UV detection. The unknown impurity structure was proposed as 4-[2-(propan-2-ylamino)ethyl]benzene-1,2-diol (Imp-II) using the liquid chromatography--mass spectrophotometry (LC--MS) analysis. Imp-II was isolated by semi-preparative liquid chromatography from the impurity-enriched reaction crude sample. Its proposed structure was confirmed by nuclear magnetic spectroscopy such as 1H, 13C, DEPT (1D NMR), HSQC (2D NMR) and infrared spectroscopy (IR), and retention time and purity with HPLC followed by the chemical synthesis. Due to less removable nature of Imp-II during the purification, the synthetic process was optimized proficiently to control the formation of Imp-II below to the limit<0.12% in the course of reaction. The new chemical route was developed for the preparation of this impurity in required quantity with purity to use as reference standard. The most probable mechanism for the formation of Imp-II was discussed in details.

5.
J Pharm Biomed Anal ; 133: 15-26, 2017 01 30.
Article in English | MEDLINE | ID: mdl-27969063

ABSTRACT

Four impurities (Imp-I-IV) were detected using gradient HPLC method in few laboratory batches of acrivastine in the level of 0.03-0.12% and three impurities (Imp-I-III) were found to be known and one (Imp-IV) was unknown. In forced degradation study, the drug is degraded into four degradation products under oxidation and photolytic conditions. Two impurities (Imp-III and -IV) were concurred with process related impurities whereas Imp-V and -VI were identified as new degradation impurities. Based on LC-ESI/MSn study, the chemical structures of new impurities were presumed as 1-[(2E)-3-(4-methylphenyl)-3-{6-[(1E)-3-oxobut-1-en-1-yl]pyridin-2-yl}prop-2-en-1-yl]pyrrolidin-1-ium-1-olate (Imp-IV), 1-{[3-(4-methylphenyl)-3-{6-[(1E)-3-oxobut-1-en-1-yl]pyridin-2-yl}oxiran-2-yl]methyl}pyrrolidin-1-ium-1-olate (Imp-V) and 2-[2-(4-methylphenyl)-3-[(1-oxidopyrrolidin-1-ium-1-yl)methyl]oxiran-2-yl]-6-[(1E)-3-oxobut-1-en-1-yl]pyridin-1-ium-1-olate (Imp-VI), and confirmed by their synthesis followed by spectroscopic analysis, IR, NMR (1H, 13C) and mass. An efficient and selective high-performance liquid chromatography method has been developed and resolved well the drug related substances on a Phenomenex Gemini C-18 (250×4.6mm, particle size 5µm) column. The mobile phase was composed of sodium dihydrogen phosphate (10mM) and methanol, temperature at 25°C, and a PDA detector set at 254nm used for detection. The method was validated with respect to specificity, linearity, precision, accuracy, and sensitivity and satisfactory results were achieved. Identification, synthesis, characterization of impurities and method validation were first reported in this paper.

6.
J Pharm Biomed Anal ; 120: 248-60, 2016 Feb 20.
Article in English | MEDLINE | ID: mdl-26760243

ABSTRACT

Five process-related impurities were detected in the range of 0.08-0.22% in ticagrelor laboratory batches by HPLC and LC-MS methods. These impurities were named as TIC Imp-I, -II, -III, -IV and -V. Four of these impurities, TIC Imp-I to -IV were unknown and have not been reported previously. Based on LC-ESI/MS(n) study, the chemical structures of new impurities were presumed as (1S,2S,3S,5S)-3-(2-hydroxyethoxy)-5-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d] pyrimidin-3-yl)cyclopentane-1,2-diol (TIC Imp-I), (1S,2S,3S,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (TIC Imp-II), (1S,2R,3S,4S)-4-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol (TIC Imp-III) and (3S,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (TIC Imp-IV). The unknown impurities were isolated from enriched crude sample by column chromatography and preparative HPLC. The complete spectral analysis, MS, 1D NMR ((1)H, (13)C and DEPT), 2D NMR (HSQC and HMBC) and IR confirmed the proposed chemical structures of impurities. Identification, isolation, structural characterization, prospects for the formation of impurities and their synthesis were first reported in this paper.


Subject(s)
Adenosine/analogs & derivatives , Drug Contamination , Magnetic Resonance Spectroscopy/methods , Spectrometry, Mass, Electrospray Ionization/methods , Tandem Mass Spectrometry/methods , Adenosine/chemistry , Adenosine/isolation & purification , Chromatography, High Pressure Liquid/methods , Chromatography, Liquid/methods , Ticagrelor
7.
Eur J Med Chem ; 107: 219-32, 2016 Jan 01.
Article in English | MEDLINE | ID: mdl-26588065

ABSTRACT

A series of fused tricyclic coumarin derivatives bearing iminopyran ring connected to various amido moieties were developed as potential multifunctional anti-Alzheimer agents for their cholinesterase inhibitory and radical scavenging activities. In vitro studies revealed that most of these compounds exhibited high inhibitory activity on acetylcholinesterase (AChE), with IC50 values ranging from 0.003 to 0.357 µM which is 2-220 folds more potent than the positive control, galantamine. Their inhibition selectivity against AChE over butyrylcholinesterase (BuChE) has increased about 194 fold compared with galantamine. The developed compounds also showed potent ABTS radical scavenging activity (IC50 7.98-15.99 µM). Specifically, the most potent AChE inhibitor 6n (IC50 0.003 ± 0.0007 µM) has an excellent antioxidant profile as determined by the ABTS method (IC50 7.98 ± 0.77 µM). Moreover, cell viability studies in SK N SH cells showed that the compounds 6m-q have significant neuroprotective effects against H2O2-induced cell death, and are not neurotoxic at all concentrations except 6n and 6q. The kinetic analysis of compound 6n proved that it is a mixed-type inhibitor for EeAChE (Ki1 0.0103 µM and Ki2 0.0193 µM). Accordingly, the molecular modeling study demonstrated that 6m-q with substituted benzyl amido moiety possessed an optimal docking pose with interactions at catalytic active site (CAS) and peripheral anionic site (PAS) of AChE simultaneously and thereby they might prevent aggregation of Aß induced by AChE. Furthermore, in silico ADMET prediction studies indicated that these compounds satisfied all the characteristics of CNS acting drugs. Most active inhibitor 6n is permeable to BBB as determined in the in vivo brain AChE activity. To sum up, the multipotent therapuetic profile of these novel tricyclic coumarins makes them promising leads for developing anti-Alzheimer agents.


Subject(s)
Coumarins/chemistry , Coumarins/pharmacology , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Acetylcholinesterase/chemistry , Acetylcholinesterase/metabolism , Alzheimer Disease/drug therapy , Animals , Antioxidants/chemistry , Antioxidants/pharmacology , Binding Sites , Butyrylcholinesterase/metabolism , Chemistry Techniques, Synthetic , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/pharmacology , Computer Simulation , Coumarins/chemical synthesis , Drug Evaluation, Preclinical/methods , Galantamine/pharmacology , Humans , Hydrogen Peroxide/toxicity , Male , Mice, Inbred BALB C , Models, Molecular , Neuroprotective Agents/chemical synthesis , Neurotoxicity Syndromes/etiology
8.
J Pharm Biomed Anal ; 119: 114-21, 2016 Feb 05.
Article in English | MEDLINE | ID: mdl-26678178

ABSTRACT

Vildagliptin is a member of a new class of oral anti-diabetic drug. One unknown impurity was identified in the range of 0.01-0.06% in different laboratory batches of vildagliptin along with known impurities by HPLC analysis. The structure of unknown impurity was proposed as (2S)-1-[2-[(3-hydroxyadamantan-1-yl)imino]acetyl]pyrrolidine-2-carbonitrile (Impurity-E) using LC/ESI-MS(n) study. The unknown impurity was found to be unstable in diluent (H2O:CH3CN) and degrading into another stable impurity. The degraded stable impurity was isolated from enriched reaction crude sample by semi preparative liquid chromatography. The structure of stable impurity was established using FT-IR, NMR ((1)H, (13)C and DEPT), 2D NMR (HSQC, HMBC and COSY) and mass spectral data as (8aS)-3-hydroxy-octahydropyrrolo[1,2-a]piperazine-1,4-dione (Impurity-F). Impurity identification, abnormal behaviour of impurity-E, isolation of impurity-F, fragmentation mechanism and structural elucidation were also discussed.


Subject(s)
Adamantane/analogs & derivatives , Dipeptidyl-Peptidase IV Inhibitors/analysis , Drug Contamination/prevention & control , Nitriles/analysis , Pyrrolidines/analysis , Pyrrolidines/isolation & purification , Technology, Pharmaceutical/methods , Adamantane/analysis , Adamantane/isolation & purification , Chromatography, High Pressure Liquid , Molecular Structure , Spectrometry, Mass, Electrospray Ionization , Technology, Pharmaceutical/standards , Vildagliptin
SELECTION OF CITATIONS
SEARCH DETAIL
...